



Session II. Liver fibrosis in NASH: A Roadmap for Drug Discovery and Pharmacotherapy

DETLEF SCHUPPAN

- Which mechanisms of hepatic fibrogenesis are amenable to drug intervention ?
- What are the most promising molecular targets for an antifibrotic drug ?
- Is the dichotomy antifibrotic drugs vs anti-inflammatory drugs justified?
 - Does an antifibrotic action require an anti-inflammatory mechanism or is a purely antifibrotic drug sufficient to improve fibrosis long-term ?

ARUN SANYAL

- How to best measure the antifibrotic effect in a human trial?
- What benefits for disease progression can we expect from an antifibrotic drug candidate ?
 - Optimal endpoints for antifibrotic drugs and trial development issues
 - What would a combo therapy, anti-NASH and antifibrosis, look like ?